By Roman Aglaganov
OpenAI announced on 20 October that it is acquiring Orchestra Bio, a startup that builds AI agents for biotech companies. The terms were not disclosed.
What Orchestra does
Orchestra, founded four years ago, works on the operational side of drug discovery rather than the chemistry: its agents track finances and sort out problems such as clinical trial scheduling. It had reportedly raised about $20 million, from investors including Andreessen Horowitz, Atria and 8VC.
Where it fits
OpenAI says Orchestra’s team and technology will join Rosalind, its AI model for life-sciences research, and Rosalind Workbench, a tool that helps scientists plan experiments and analyse results. OpenAI names Moderna and Novo Nordisk among Rosalind’s customers.
Why it matters
The big labs are no longer content to sell a general model and let others build the industry software on top. OpenAI and Anthropic are both building products for specific sectors, with pharma one of the richest. For startups in those sectors, the fear has been that a lab will ship their product as a feature. Orchestra shows the other outcome: being bought rather than squeezed out.
